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This report presents health agency leadership 
perspectives from nine states on how 
prescription drug overdose has emerged 
as a national public health problem. It also 
shows the increasing awareness of the 
problem, which prevention and monitoring 
strategies have shown promise, and the 
infrastructure, technology, prevention, 
partnership, and leadership required to 
combat comprehensively and to reverse this 
rising trend.
Since 1999, abuse, misuse, and overdose 
of prescription drugs have significantly 
increased. Each year more than 20,000 
persons in the United States die from drug 
overdose. Those with the highest rates are 
adults ages 35-44 and persons living in the 
South and West regions of this country. 
Opioid drugs, commonly prescribed to relieve 
pain, are the most common source of drug 
overdose deaths.
This increase in drug overdoses has created 
a considerable public health burden, and 
many states lack the capacity, personnel,
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and infrastructure to respond adequately 
to this emerging threat. Nonetheless, State 
and Territorial Health Officials (SHO) 
clearly recognize this problem and have 
demonstrated leadership in responding to and 
the planning for this threat.
To assess the knowledge, response, and 
planning regarding prescription drug misuse 
and overdose, in late 2007 the Association 
of State and Territorial Health Officials 
(ASTHO) and the Centers for Disease Control 
and Prevention (CDC) conducted interviews 
with SHOs and other senior leaders in nine 
states. This report outlines the knowledge, 
perceptions, partnerships, recommendations, 
policies, and other issues that are fundamental 
to understanding and responding to drug 
misuse. The following states are included 
in this report: Arkansas, Florida, Indiana, 
Kentucky, Montana, North Carolina, 
Oklahoma, Utah, and West Virginia.
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Key Interview Findings:
► Most State Health Agencies (SHA) 
recognized that prescription drug 
overdoses were a growing issue but 
in some cases only recently realized 
its magnitude. Most agencies 
became aware of the overdose 
problem through mortality data.
► States rely heavily on measures 
such as interagency task forces 
and prescription monitoring 
programs to address the problem. 
Less common are educational and 
regulatory initiatives.
► States cited insufficient data, 
privacy and confidentiality 
concerns, and lack of state- 
based injury prevention capacity 
as barriers to implementing a 
response.
► States recognized the need to 
increase the visibility of the 
prescription drug overdose 
problem.
► States also identified the potential 
effectiveness of evidence-based 
guidelines for prescribers and 
for policy and programmatic 
tools. Although many states have 
implemented responses, their 
effectiveness is unclear.
Recommendations:
► SHAs should routinely track all 
major causes of injury. To increase 
public and professional awareness 
of the drug problem, states should 
emphasize its magnitude and 
rapid growth—the many young 
lives that are cut short and the 
mounting costs for state programs, 
law enforcement, Medicaid, and 
substance abuse treatment.
► State governments should identify 
a “home” for coordinating the 
response to the drug overdose 
problem. Prevention, surveillance, 
and response are often too 
fragmented across agencies and 
divisions of state government.
► States should build their capacity 
by using cost savings from 
reducing fraud and abuse involving 
prescription drugs to fund overdose 
prevention as part of SHA injury 
prevention. They should address 
privacy, confidentiality, and other 
concerns about prescription-drug 
monitoring programs (PDMP) by 
emphasizing to physicians the value 
of knowing which of their patients 
are abusing medications and the 
value of prosecuting unscrupulous 
providers.
► SHAs should rigorously evaluate 
the effect of prevention and control 
efforts on health outcomes.
2 Prescription Drug Overdose: State Health Agencies Respond ASTHO © 2008
Between 1999 and 2005, the annual number 
of unintentional drug overdose deaths in 
the United States more than doubled—from 
11,155 to 22,448. Drug overdose became 
the second leading cause of unintentional 
injury death in the nation in 2002, just behind 
motor-vehicle injuries. The 35-44 age group 
had the largest increase.1
A 2006 CDC report showed that the rise in 
drug overdose mortality was due to increasing 
deaths from prescription 
drugs rather than from 
illicit drugs such as heroin 
and cocaine. The primary 
problem was a class of 
prescription drugs known 
as opioid analgesics.2 
These drugs are powerful 
painkillers with a potential 
for abuse because of 
their heroin-like effect.
Physicians increasingly 
prescribed these drugs
during the 1990s to treat moderate and severe 
pain. However, their potential for misuse 
was underestimated, and opioid analgesics 
quickly became the most popular category of 
abused drugs. By 2007, more teenagers used 
opioid analgesics recreationally than used 
marijuana.3
In 2000, publicity about prescription drug 
abuse focused on OxyContin®, a powerful 
opioid painkiller. Today, however, the most 
common opioid involved 
in drug overdose deaths 
has become the pill form 
of methadone, which 
is increasingly used as 
a painkiller because 
it costs twenty times 
less than drugs such as 
OxyContin®.4 From 
1997-2006, the sales of 
Oxycontin®, methadone, 
and other opioids increased 
substantially.5
Total Unintentional and 
Undetermined Intent Drug 
Overdose Deaths, 2005
Arkansas: 221 
Florida: 2,003 
Indiana: 526 
Kentucky: 586 
Montana: 71 
North Carolina: 848 
Oklahoma: 405 
Utah: 389 
*West Virginia: 169
Source: CDC W ONDER
O ff ic ia l 2005 drug po ison ing m orta lity  data 
fo r  W est Virginia is  incomplete.
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This drug overdose epidemic hit some parts 
of the country particularly hard. More than 
half of the country—particularly Southern 
and Midwestern states— saw their drug 
mortality rates double. West Virginia’s rate 
increased over 500 percent, while rates in 
Oklahoma, Montana, and Arkansas tripled. 
Increases were generally greater in more rural 
states.1
Rates of both use and misuse of opioid 
analgesics are highest in low-income 
populations that likely rely on Medicaid, 
so the social costs of this problem are 
significant. One national evaluation of insured 
populations found that opioid abusers had 
mean annual direct health care costs eight 
times higher than nonabusers.6 Another 
study estimated that the total costs for opioid 
abuse was $8.6 billion in 2001 dollars. Direct 
healthcare costs accounted for $2.6 billion, 
and lost productivity totaled $4.6 billion.
The costs in 2005 dollars would be $9.5 
billion.7 Given the substantial increase in drug 
overdose in recent years, economic costs are 
expected to be significantly higher in 2008.
Within the public sector, law enforcement 
agencies have traditionally been responsible 
for preventing and responding to drug abuse. 
SHAs have typically served supporting roles, 
such as providing mental health and substance 
abuse treatment programs. With the change 
to a drug abuse problem that is increasingly 
related to prescribed pharmaceuticals, the 
role of SHAs has expanded. At the same 
time, state drug control offices have shifted 
emphasis from illegal drug control to 
preventing prescription drug misuse.
The problem impacts SHAs in numerous 
ways. It affects state Medicaid and workers’ 
compensation programs, which pay for 
both the prescription drugs and the medical 
care necessary to treat overdoses among 
low-income and disabled populations. The 
prescriptions for these drugs are written 
by physicians and dentists and dispensed 
by pharmacists, all of whom are licensed
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by state licensing boards, which 
frequently sit within SHAs. These 
agencies are also often the home of 
prescription monitoring programs, 
which track prescriptions for 
controlled substances, including 
opioid painkillers and sedatives. 
Finally, SHAs are leaders and 
experts in collecting relevant data 
about mortality, hospitalization, 
and emergency department 
visits for problems such as drug 
overdose.
SHAs play a growing role in 
addressing the rise in prescription 
drug overdoses through disease 
surveillance and data collection, 
education and outreach, policy 
development, and coalition 
building. As leaders of these 
agencies, State and Territorial 
Health Officials (SHOs) play 
a critical role in determining 
the scope and effectiveness of 
their agencies’ responses to this 
problem.
State Health Officials and Other Interview Participants
Arkansas: Paul Halverson, DrPH, FACHE, Director and State 
Health Officer; Jerry Jones, Pharmacy Director; Jodianne Tritt, JD, 
Director of Community Support; Charles McGrew, Deputy Director 
and Chief Operating Officer, Arkansas Department of Health
Florida: Ana Viamonte Ros, MD, MPH, Secretary of Health and 
Surgeon General; Rich Weismann, Poison Control Director,
Florida Department of Health; Bill Janes, Director, Florida Office 
of Drug Control
Indiana: Judith A. Monroe, MD, FAAFP, State Health 
Commissioner, Indiana State Department of Health
Kentucky: William Hacker, MD, FAAP, CPE, Commissioner of 
Public Health, Kentucky Cabinet for Health and Family Services
Montana: Todd Harwell, MPH, Chief, Chronic Disease Prevention 
and Health Promotion Bureau; Bobbi Perkins, EMT-B, Injury 
Prevention Program Manager; Roger Citron, RPh, Medicaid 
Pharmacist; Steven Helgerson, MD, MPH, State Medical Officer, 
Montana Department of Public Health and Human Services
North Carolina: Leah Devlin, DDS, MPH, State Health Director; 
Marcus Plescia, MD, Chief of Chronic Disease and Injury Section, 
North Carolina Division of Public Health
Oklahoma: Mike Crutcher, MD, MPH, Commissioner of Health; 
Shelli Stephens Stidham, Chief, Injury Prevention Service, 
Oklahoma State Department of Health
Utah: Bob Rolfs, MD, MPH, State Epidemiologist, Utah 
Department of Health
West Virginia: Chris Curtis, MPH, Acting Commissioner; Jim 
Kaplan, MD, Chief Medical Examiner; John Wilkinson, Director, 
Office of Health Facilities Licensure; Aron Hall, DVM, MSPH, CDC 
Epidemic Intelligence Service Officer; Danae Bixler, MD, MPH, 
Bureau of Public Health, West Virginia Department of Health & 
Human Resources
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To better understand the prescription 
overdose problem at the state level, CDC 
funded ASTHO through an existing 
cooperative agreement to conduct interviews 
with nine SHOs during the fall of 2007.
doubled from 1999 to 2004. Care was taken 
to include geographic and social diversity 
among the sample in addition to including 
those states that had expressed an interest in 
participating.
The Assessment Process
The goals of the interviews were to:
► Understand SHOs’ awareness about 
the problem of prescription drug 
overdoses.
► Learn about state responses to the 
problem.
► Identify perceived barriers to 
addressing the problem.
► Identify SHOs’ perceived needs 
to better address their state’s 
prescription drug overdose 
problems.
Participants were selected from 19 states 
with at least 50 nonsuicidal drug overdose 
deaths in 2004 and overdose rates that at least
SHOs from the nine states were encouraged 
to invite a small group of program experts, 
leaders from partner agencies, and others to 
attend the interview and to provide expertise 
and perspectives. Interviews were conducted 
by telephone in October and November 2007, 
and lasted for about 30 minutes. Respondents 
could review the transcripts for accuracy and 
clarity. Participants’ quotes in this report are 
typically, but not always, verbatim.
Seven SHOs were interviewed. In addition, 
interviewees included state epidemiologists, 
state injury prevention directors, leaders of 
state drug control offices, and other relevant 
state health and substance abuse staff.
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This section describes the .ndings from 
the SHO interviews, which are organized 
according to the specific study goals. 
Themes are presented when appropriate and 
illustrative quotes are used to reinforce key 
points.
Interview Guide
CDC and ASTHO developed a semi-structured
interview guide that included a series of open-
ended questions:
• Tell me what you know about prescription 
drug overdoses in your state.
• When did you become aware of the prescription 
drug overdose problem in your state? How
did you become aware of this problem?
• Please describe in detail your agency’s response 
to the prescription drug overdose problem.
• What in your opinion have been the most 
effective approaches to dealing with this 
problem in your state? How would you define 
success in terms of your agency’s response?
• What has motivated or facilitated your 
agency’s response to addressing the current 
prescription drug overdose problem?
• What barriers have reduced the 
effectiveness of your response?
• Historically, what has been your 
agency’s response to prescription drug 
overdose problems in your state?
• Talk about what you think your agency’s 
role should be in addressing this and future 
prescription drug misuse problems.
State Health Agency Awareness
When asked how they became aware of the 
prescription overdose problem, interviewees 
typically had a general sense of the overall 
numbers of deaths and other health outcomes 
associated with drugs or prescription drugs. 
All were aware that they had a growing 
problem in their states. A wide variation 
existed in when they became aware of the 
problem, ranging from the mid-1990s to 
2007, the year of the interviews.
Several states indicated that data from state 
medical examiners were the primary source 
of their information. Other sources included 
media reports and national reports in public 
health literature.
KENTUCKY -  William Hacker: “The 
prescription drug overdose problem 
has grown consistently over the past 10 
years. We became more aware of the 
problem due to better data. Although no 
single event raised our awareness, over 
the years several anecdotal stories of 
overdoses both accidental and intentional 
have been shared in the media."
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NORTH CAROLINA -  Leah Devlin: “We 
lose over 700 people from unintentional 
overdoses each year. The big ones 
are methadone and OxyContin. It’s a 
multifactorial problem."
WEST VIRGINIA -  Jim Kaplan: “We began 
to see an upward trend in toxicology 
fatalities around 1997-1998. We began 
to see general trending of the methadone 
problem in 2002-2003."
UTAH -  Bob Rolfs: “Somewhere around 
2000, the medical examiners noticed a 
trend. Previously, there were about 30-40 
deaths per year in prescription opioid use. 
That jumped to somewhere around 250."
Unintentional and undeterm ined intent drug poisoning mortality 
rates by year, se lected  states and th e  U.S., 1999-2005
20
°  15o  ±=>
CD
o
o
<D
Q .
OJ4—*TO
CC
10
2005
2004
2003
2002
2001
2000
1999
I I W  I I W  I I W  I
AR FL IN KY MT NC OK UT WV* US
* O fficia l 2005 drug overdose m orta lity  data fo r  W est Virginia is incomplete.
5
0
State Health Agency Responses to 
the Problem
Although SHA responses to the problem 
varied, certain activities were frequently 
reported. They included state task forces, 
implementing state prescription drug 
monitoring programs (PDMPs), and linking 
state-managed databases.
Creating State Task Forces
In many cases, either the SHA or another 
state agency had convened representatives 
from various components of their respective 
governments— and in some instances 
members of the community. For example, 
Bill Janes, Director of Florida’s Office 
of Drug Control, described a drug control 
advisory council with members from 
public health, law enforcement, other state 
agencies, the community, and the Governor’s 
office. William Hacker noted that in 2004, 
Kentucky created the Governor’s Office 
of Drug Control Policy within the Justice 
and Public Safety Cabinet to coordinate 
state agency efforts. Several states reported
creating task forces in which members were 
drawn from mental health and substance 
abuse agencies, law enforcement, offices 
of drug control, pharmacy boards, coroner/ 
medical examiners, workers’ compensation, 
Medicaid, public employees’ insurance 
programs, medical licensing boards, medical, 
dental, and pharmacist associations, and 
other non-governmental stakeholders. West 
Virginia’s “Controlled Substance Advisory 
Board Workgroup” similarly convenes key 
statewide stakeholders to identify priorities 
and to develop strategies.
Some participants thought that forming a task 
force was a critical early step:
NORTH CAROLINA -  Leah Devlin: “ In 
2002, our Epidemiology Officer and the 
Secretary of the Department helped 
create a 25-member task force to help 
deal with the issue. They came up with 48 
recommendations of what we should do.
The task force was key. It brought together 
law enforcement, mental health and 
public health. This was the first time the 
issue was addressed with a collaborative 
approach."
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Implementing State Prescription Drug 
Monitoring Programs
States frequently cited prescription 
drug monitoring programs as tools to 
monitor prescription sales of controlled 
substances, such as opioid analgesics and 
benzodiazepines (see inset).
Some SHAs are making extensive use of their 
PDMP data for surveillance and evaluation:
KENTUCKY -  William Hacker: “Ten years 
ago the Department of Public Health 
established an electronic reporting system, 
Kentucky All Schedule Prescription 
Electronic Reporting (KASPER) to track 
controlled substances dispensed within 
the state. KASPER is designed to provide 
information to physicians and pharmacists 
and serve as an investigative tool for law 
enforcement. For example, if a physician 
sees a patient that exhibits drug seeking 
behavior, he/she can access KASPER 
online or by phone to find out if any other 
provider or pharmacist has prescribed 
narcotics and when. The system’s benefits 
also include that high quality care is 
provided to those patients who truly need 
prescription drugs. The KASPER program 
is now housed in the Cabinet’s Office 
of Inspector General and continues to 
be the primary data source that guides 
prescription drug overdose prevention 
efforts of the Department of Public Health."
State Prescription Drug Monitoring 
Programs
Prescription Drug Monitoring Programs 
(PDMP), have been implemented in 26 
states and nine more are in the development 
phase according to the U.S. Department of 
Justice. PDMPs create statewide databases 
to monitor prescriptions and to identify 
patients who may “doctor shop" or forge 
prescriptions to illegally obtain large amounts 
of drugs. They can also identify physicians 
who are prescribing especially large quantities 
of drugs. Most programs provide patient- 
specific drug information upon request of the 
patient’s physician or pharmacist. Some state 
programs proactively notify physicians when 
their patients are seeing multiple prescribers 
for the same class of drugs.
The number of states with prescription 
monitoring programs has grown rapidly 
in recent years, driven in part by financial 
support from the Department of Justice 
through the Harold Rogers Program. Among 
the nine states included in this report, PDMPs 
operate in six: Indiana, Kentucky, North 
Carolina, Oklahoma, Utah, and West Virginia. 
Only Indiana and Oklahoma’s PDMPs were 
enacted prior to 1990; the others were all 
enacted in 1995 or later.
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FLORIDA -  Ana Viamonte Ros reported, 
in 2007, that Broward County began to 
pilot a local database that could then be 
used statewide. Advocates hope that 
a pilot in such a populated county will 
demonstrate both the effectiveness and 
confidentiality of the PDMP and make 
future implementation possible.
WEST VIRGINIA -  John Wilkinson, 
reported data sharing within the Bureau 
for Public Health: The Office of Health 
Facility Licensure and Certification has 
shared information on participation in state 
narcotics treatment programs by people 
dying of drug overdoses with the Office of 
the Chief Medical Examiner.
WEST VIRGINIA -  Danae Bixler: “Our 
(PDMP) data suggest that the problem 
is mixed: a substantial proportion of fatal 
cases had prescriptions for the drugs that 
killed them—often from multiple physicians 
and multiple pharmacies. In other cases, 
many decedents did not have prescriptions 
for at least one drug identified in post­
mortem toxicology. This suggests that 
a substantial proportion of decedents 
are getting prescriptions directly from 
physicians and the others are getting drugs 
through diversion [to nonpatients].”
Other Data Collection and Sharing Efforts
Respondents mentioned several data
collection or sharing efforts.
UTAH -  The state is trying to link data from 
the state prescription monitoring program 
with the state medical examiner’s and 
emergency department databases.
WEST VIRGINIA -  Aron Hall, CDC 
Epidemic Intelligence Service Officer, 
mentioned a recent collaborative 
investigation of drug overdose deaths 
in West Virginia. The investigation 
involved the CDC, West Virginia Office 
of Epidemiology and Health Promotion, 
Office of the Chief Medical Examiner,
Board of Pharmacy, and statewide opiate 
treatment programs. Investigators from 
CDC abstracted data in collaboration with 
each of these entities to describe risk 
factors for fatal drug overdose and patterns 
of prescription drug abuse.
MONTANA -  The state is currently 
linking medical examiner records on drug 
overdose deaths with Medicaid files to 
examine the prescribing patterns, co­
morbidities, and costs associated with 
such deaths.
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Public and Provider Education
State health departments have also taken 
advantage of their existing contacts with the 
community:
FLORIDA -  Bill Janes: “There are many 
(statewide) coalitions and community 
efforts to increase awareness, but we must 
do a better job of reaching our families.”
INDIANA -  In Indiana, law enforcement 
maintains issue jurisdiction, but the Indiana 
State Department of Health has offered 
outreach and education to healthcare 
providers who prescribe drugs, and to 
statewide media to encourage responsible 
and educational reporting.
WEST VIRGINIA -  The West Virginia 
University School of Medicine offers two 
CME courses entitled, “Clinical Challenges 
in Prescribing Controlled Drugs.” The 
courses present provider education to help 
guide the judicious use of controlled drugs, 
balancing the needs of patients with the 
risks of abuse and diversion.
FLORIDA -  Bill Janes described an 
electronic prescribing initiative that 
passed the Florida Legislature in 2007. 
“While we continue to work to implement 
a prescription drug monitoring database,
I believe e-prescribing is the system 
of the future. It is more timely and less 
expensive. The problem is most doctors 
do not e-prescribe and this solution is 
probably not achievable in the immediate 
future.” Florida’s e-prescribing legislation 
requires a state agency to
• Create a clearinghouse of 
information on electronic 
prescribing,
• Create a Web site to provide 
healthcare providers with 
information about the process 
and advantages of electronic 
prescribing, software availability, 
and state and national initiatives 
on electronic prescribing.
• Convene quarterly meetings 
of stakeholders to assess 
implementing e-prescribing.
In Palm Beach County, a Good Samaritan 
law protects citizens who help anyone who 
is overdosing.
Regulatory or Legislative Initiatives
States have rules and laws that might affect 
the use of controlled prescription drugs and 
related overdoses.
MONTANA -  The state requires Medicaid 
clients to obtain preauthorization for certain 
drug prescriptions. Medicaid only covers 
preauthorized prescriptions.
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Creating Programs
States provided many examples of 
government programs that addressed aspects 
of population-based services and patient care.
ARKANSAS -  The Arkansas Department 
of Health is working with the state 
coroners’ association and others to get 
prescription opioids and other drugs out 
of the homes of people who have recently 
died at home so they do not fall into the 
hands of drug abusers. Arkansas also has 
a drug destruction program to ensure that 
the drugs are properly disposed of when 
found in homes.
KENTUCKY -  The Kentucky Department 
of Mental Health and Mental Retardation 
received a grant to address substance 
abuse. One of its programs uses clinicians 
and other professionals to focus on 
outreach to communities with high rates 
of substance abuse. Initial results show 
promise. Data will be available next year.
In addition, Kentucky created a public 
health program that screens all pregnant 
women for substance abuse.
MONTANA -  The state created a case- 
management program within Medicaid.
Clients who use multiple pharmacies 
and prescribers are designated to one 
physician and one pharmacy for all 
controlled substance prescriptions.
Tracking State Health Agency Actions
Most respondents acknowledged that, while 
awareness is growing within their agencies, 
the response to the problem has not matched 
the extent of the burden. Furthermore, states 
could not conduct enough formal prevention 
programs to permit critical assessment and 
evaluation. Therefore, much of what is known 
is anecdotal or incomplete.
INDIANA -  Judith Monroe noted that 
Indiana State Department of Health’s 
outreach to statewide media and providers 
has increased awareness and discussions 
about drug overdose— but unfortunately, 
this awareness has not translated to a 
decrease in mortality rates.
KENTUCKY -  The state is evaluating the 
results of its community outreach program. 
Initial results show promise. Final results 
should be available next year. Kentucky 
also noted promising research on the 
effectiveness of substance abuse courts 
ordering treatment and close monitoring 
rather than incarceration for drug-related 
crimes.
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Barriers to Addressing the Problem
SHOs noted many barriers to addressing the 
drug overdose problem. Limited awareness of 
the extent of the unintentional drug overdose 
problem was a common theme:
ARKANSAS -  Paul Halverson: “We have 
terrible statistics, but no one talks about it.”
NORTH CAROLINA -  Leah Devlin: “I don’t 
think people are aware of this as an issue. 
We’ve been trying to get this through for 
ten years.”
When discussing data collection and sharing 
issues, particularly PDMPs, privacy and 
liability concerns were a common theme. 
Patients and their advocates are concerned 
that their medical information may be 
scrutinized without permission by persons 
other than healthcare providers, such as 
law enforcement. Healthcare providers are 
concerned that their medical decision will 
be second-guessed by law enforcement 
or by malpractice attorneys. However, all 
respondents indicated that the most stringent 
privacy protections are implemented at 
SHAs to protect patient confidentiality and
to ensure that databases are used only to 
maintain the public’s health. PDMPs are 
obliged to consider stakeholder privacy and 
confidentiality concerns. SHOs emphasized 
their agencies’ histories of protecting sensitive 
health information and that SHAs have the 
appropriate education, policy, and technical 
infrastructure to be responsible data stewards.
FLORIDA -  Privacy concerns are common 
barriers that prevent implementing 
PDMPs. As Florida’s Ana Viamonte Ros 
reported in 2007, Broward County began 
to pilot a local database that could be 
used statewide. Advocates hope that 
a pilot in such a populated county will 
demonstrate both the effectiveness and 
con.dentiality of the PDMP and facilitate 
future implementation.
NORTH CAROLINA -  Leah Devlin: “There 
is a huge privacy issue. It does seem very 
‘big brother,’ where drugs are put in a 
database. It freaks people out.”
An additional barrier regarding PDMPs 
was convincing pharmacists that the burden 
of reporting prescription information was 
small and justified given the importance of 
preventing drug misuse.
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Also, respondents raised concerns that 
attention to this issue might cause physicians 
to cut back on prescribing opioid painkillers 
to the point where some people’s pain might 
be undertreated.
UTAH -  Bob Rolfs: “We under-treat pain, 
but now there is a push to treat pain more. 
(Prescription misuse) could be an offshoot 
of that. But we don’t necessarily want to 
scale back and go back to under-treating 
patients. We need to find the balance 
between treating the people who need 
more and preventing overuse.”
With respect to mounting a response to 
prescription misuse, the most common 
obstacle cited was lack of funding both to 
identify the sources of the problem and to 
provide treatment for people with substance 
abuse problems. In North Carolina, it 
was noted that substance abuse treatment 
programs were not readily available, 
especially in rural areas.
The theme of lack of capacity within SHAs 
for injury prevention in general is also related 
to this issue. As Paul Halverson of Arkansas 
put it, “We have no injury capacity in this
state. It’s embarrassing that we, state and 
nationally, don’t have staff to work on the 
number one issue for 1 to 44 year-olds— 
unintentional injury.”
Montana staff also noted that their state did 
not have a well-organized injury prevention 
program. In other states with injury programs, 
participants noted that drug overdoses still 
had to compete for attention with other injury 
priorities.
Future Needs — What Should 
Health Agencies be Doing?
Respondents noted many potential areas 
where prevention efforts have been suggested, 
proposed, or implemented. SHOs and others 
laid out their priorities in addressing future 
issues:
ARKANSAS -  Paul Halverson: “What 
I would like is a good, efficient drug 
monitoring program. We have to stop 
doctor shopping and inappropriate 
prescriptions. Doctors should know whom 
else the patient is seeing. Building the 
database to prevent abuse is critical. It is 
not intended as a police mechanism— it 
is truly to enhance the public’s health by 
being an informational tool.”
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FLORIDA -  Ana Viamonte Ros: “We 
need to understand the best practices of 
other states and how they have overcome 
obstacles. We need to strengthen rules 
for enforcement and increase availability 
for health insurance and rehabilitation 
services. Unifying mental health and 
substance abuse is very important, 
along with the education and awareness 
message.”
KENTUCKY -  William Hacker: “We need 
to improve collaboration between state 
agencies and other partners. As linkages 
continue to build, partners can share their 
individual passions with one another to 
address community needs at both the 
macro and micro levels. This problem will 
not be solved in a decade, maybe several. 
It is necessary to keep the issue in front of 
both the general assembly and executive 
branch.”
NORTH CAROLINA -  Leah Devlin: “Were 
an aging state. As we get older we’ll see 
more in pain. We will have to do more 
prevention.”
UTAH -  Bob Rolfs: “We need to keep this 
issue at a high level to continue working 
on things. We need to involve public 
education, guidelines for physicians that 
are evidence based, and we need to 
understand the problem better, including 
the epidemiology of it. At a micro-level, 
our focus has been analyzing secondary
data. We need to get prospective data to 
get a real understanding of the issue. In 
the meantime, we know enough to keep 
going.”
WEST VIRGINIA -  Chris Curtis: “We 
need more prevention efforts. We can’t 
do it ourselves, we need to engage all 
the players to work with us. Public health 
needs to validate the extent of the problem 
and work with our partners to educate 
and prevent. It’s not only a public health 
issue, it’s a medical care issue because 
these drugs are prescribed by private 
practitioners.”
The states chosen for this assessment 
represent a cross-section of jurisdictions with 
sharp increases in prescription drug overdose 
deaths since 1999. ASTHO and CDC sought 
to include a geographic, demographic, 
and cultural mix of states to best capture 
national trends for such an emerging public 
health challenge. Not surprisingly, the 
SHO interviews yielded an impressive 
array of needs, priorities, challenges, and 
recommendations— although many common 
themes arose.
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Collectively, SHOs and their leadership teams 
identi.ed these most common problems, 
solutions, and conclusions:
► Most states recognize prescription 
drug overdoses as a growing issue, 
although some states only recently 
became aware of its magnitude 
locally. Most states became aware 
of the problem through mortality 
data.
► States rely heavily on measures 
such as interagency task forces 
and prescription monitoring 
programs to address the problem.
Less common are educational and 
regulatory initiatives.
► States cited lack of awareness 
of the problem, insufficient 
data, privacy and confidentiality 
concerns, and lack of state- 
based injury prevention capacity 
as barriers to implementing a 
response.
► States cited the need to increase 
the visibility of the prescription 
overdose problem.
► States need evidence-based 
guidelines for prescribers and 
effective policy and programmatic 
tools. Although many states have 
implemented responses, their 
effectiveness is unclear.
Many of these issues reach beyond the scope 
of this singular issue. Limited capacity 
within SHAs to address injury prevention 
impedes progress on the nation’s fifth 
leading cause of death, while also impairing 
opportunities to study, prevent, and educate 
about drug overdose. Privacy concerns 
related to prescription drug monitoring 
programs are common among public health 
issues, yet lessons learned from states with 
active PDMPs like Kentucky can be used 
to assuage fears and to increase national 
adoption of such programs. Cross-agency 
partnerships in states like Arkansas, 
Montana, West Virginia, North Carolina, 
and Florida present models for responding to 
health threats that can only be overcome by 
using multidisciplinary approaches. Creating 
awareness and performing public outreach, 
as is the case in Indiana, demonstrates the 
crucial need and effectiveness of health 
marketing, promotion, and education.
Utah’s mature epidemiology capacity has 
helped leaders understand, appreciate, and 
strategically address this emerging health 
threat.
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These multidisciplinary responses and 
solutions can reverse such a formidable 
trend. As ASTHO’s interviews revealed, 
SHOs are increasingly aware of the growing 
problem of drug overdose and are developing 
multifaceted approaches for prevention and 
control. While prevention infrastructure and 
capacity may not match the extent of the 
problem, innovation is both necessary and 
common, as indicated in the interviews. This 
report is a step in identifying, promoting, 
and ultimately preventing the public health 
tragedy of prescription drug abuse and 
overdoses. Continuing education is needed 
and yields results, as Indiana and West 
Virginia demonstrate. Closing infrastructure 
gaps for injury prevention and control is 
fundamental, particularly in places like 
Arkansas. And investing in sound, robust 
surveillance like Utah’s is a crucial step in 
identifying problems and targeting scarce 
prevention dollars.
State public health is but one necessary 
partner to eliminate drug overdoses;
Florida’s model partnership with drug 
control and North Carolina’s task force 
creation showcases this clearly. Identifying a 
“home” for drug abuse in state government, 
delineating clear roles for agencies, providing 
adequate surveillance and prevention 
resources, and leaders who appreciate and 
promote this issue are fundamental for 
prevention and control. ASTHO hopes 
that the findings, recommendations, and 
observations included in this report will shine 
light on the preventable cause of 20,000 
annual deaths. It also hopes to promote 
partnership and collaboration between state 
public health officials and its key internal and 
external stakeholders throughout the nation.
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Many opportunities for policy, programmatic, 
legislative, or regulatory change emerged 
from the candid responses by SHOs and 
their teams. Though each state has a unique 
policy and bureaucratic environment, there 
are several strategies to address the barriers 
and unmet needs reported by the survey 
participants, all of which may be applied in 
other jurisdictions.
► State governments should identify 
a permanent home for the response 
to the drug overdose problem. Too 
often, prevention, surveillance, 
and response are fragmented 
across agencies and divisions of 
state government. A task force is a 
useful temporary response, but is 
probably not effective as a long­
term solution.
► SHAs should routinely track 
all injury causes including drug 
overdose and track the patterns of 
drug prescriptions in their states 
using data from prescription drug 
monitoring programs.
► In addition to surveillance, 
prescription drug monitoring 
programs can be valuable as part 
of a comprehensive prevention 
program, but they alone cannot
solve the problem. To date, none 
of the PDMPs in surveyed states 
have been able to reduce the rate 
of deaths from drug overdoses. 
PDMPs may work best when 
they are proactive and paired 
with aggressive prevention, 
drug treatment, and enforcement 
components.
► To increase public and professional 
awareness, states should emphasize 
the many young lives cut short 
and the mounting costs to state 
programs, law enforcement, 
substance abuse treatment, and 
Medicaid. Medicaid recipients
are more likely to be prescribed 
narcotics8 and to die from 
prescription drug overdoses.
► States can address their lack of 
capacity in this area by showing 
that effective prevention measures 
save state dollars being spent on 
potentially unnecessary medication, 
emergency department visits for 
drug overdoses, and prescription 
fraud. Cost savings from such 
measures are greater than those 
realized by preventing illicit drug 
misuse, because the state may itself 
be paying for the drugs. Some of 
those savings could go to the SHA 
to fund an overdose prevention 
component of a state injury 
program.
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► States can address privacy, 
confidentiality and other concerns 
regarding monitoring medical care 
by emphasizing to physicians and 
pharmacists the benefit of knowing 
which of their patients are abusing 
medications and the value of 
prosecuting unscrupulous providers 
in their communities.
► States should seek the assistance of 
schools of public health, medicine, 
and pharmacy to evaluate the effect 
of policy initiatives on health 
outcomes. They should also use 
evidence-based practice guidelines 
such as the “Interagency Guideline 
on Opioid Dosing for Chronic Non­
cancer Pain,” developed by the 
Washington State Agency Medical 
Directors Group.9
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